EZH2型
医学
免疫组织化学
肿瘤科
癌症研究
内科学
病理
基因表达
生物
基因
生物化学
作者
Ying Cheng,Ying Li,Xin Huang,Wenbin Wei,Yi Qu
出处
期刊:Oncotarget
[Impact Journals LLC]
日期:2017-07-22
卷期号:8 (44): 76423-76431
被引量:22
标识
DOI:10.18632/oncotarget.19462
摘要
// Ying Cheng 1 , Ying Li 1 , Xin Huang 1 , Wenbin Wei 2 and Yi Qu 1 1 Department of Geriatrics, Qilu Hospital of Shandong University, Jinan, China 2 Beijing Tongren Hospital, Capital Medical University, Beijing Tongren Eye Center, Beijing Ophthalmology and Visual Science Key Laboratory, Beijing, China Correspondence to: Yi Qu, email: yiqucn@sdu.edu.cn Keywords: uveal melanomas, EZH2, ki-67, immunohistochemistry, prognosis Received: September 14, 2016 Accepted: June 13, 2017 Published: July 22, 2017 ABSTRACT Purpose: To analyze the prognostic value and potential target for therapeutic intervention of enhancer of zeste homologue 2 (EZH2) in uveal melanomas (UM) patients. Method: We analyzed EZH2 expression in 89 primary UM patients by immuno- histochemistry to observe the clinicopathological and prognostic value of EZH2. Results: The high levels of mitoses count and Ki67 labeling index had significant correlation with overexpression EZH2 (R = 0.408, P<0.0001; R = 0.72, P<0.0001). High level of EZH2 expression was significantly associated with increased risk of distant metastasis by the Cox proportional hazards regression model (multivariate hazard ratio: 2.12; log rank P = 0.037) and shorter UM-specific survival (multivariate hazard ratio: 3.92; log rank P = 0.036). Conclusion: Our critical finding is that overexpression EZH2 in UM can be served as predictive marker and is associated with adverse clinical outcomes. Further observation of EZH2 as a potential therapeutic target in UM is necessary.
科研通智能强力驱动
Strongly Powered by AbleSci AI